BAIYUNSHAN PH - Announcement of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.’s 2025 annual profit distribution plan and 2026 mid-term cash dividend plan
BAIYUNSHAN PH - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
The Company does not make any statement and expressly disclaims any liability arising out of or in reliance upon the whole or any part of the contents of this announcement. assumes no responsibility for any losses caused by the content.
Overseas regulatory announcement
This announcement is made in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.
This is to publish the information published by Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. (the "Company") on the website of the Shanghai Stock Exchange (www.sse.com.cn)
The full Chinese text of the company's announcement on the 2025 profit distribution plan and the 2026 mid-term cash dividend plan is for reference only.
Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.
board of directors
Guangzhou, China, March 20, 2026
As of the date of this announcement, the company’s board of directors includes executive directors Mr. Li Xiaojun, Mr. Chen Jiehui, Mr. Cheng Hongjin and Mr. Tang Heping.
and Mr. Li Hong, and independent non-executive directors Mr. Chen Yajin, Mr. Huang Min, Mr. Huang Longde and Ms. Sun Baoqing.
Securities code: 600332 Securities abbreviation: Baiyunshan Announcement number: 2026-015
Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.
2025 annual profit distribution plan and
Announcement on the 2026 mid-term cash dividend plan
The board of directors and all directors of the company guarantee that the contents of this announcement do not contain any false records, misleading statements or material omissions. leaks, and bear legal responsibility for the authenticity, accuracy and completeness of its content.
Important content reminder:
●Annual profit distribution plan for 2025: cash dividend of RMB 0.45 per share (inclusive
tax).
●Annual profit distribution in 2025 will be based on the total share capital registered on the equity registration date to implement equity distribution
is the base number, and the specific date will be clarified in the equity distribution implementation announcement. When implementing equity distribution
If the company's total share capital changes before the equity registration date, it is planned to keep the total distribution amount unchanged and adjust it accordingly.
The distribution ratio per share will be adjusted and the specific adjustments will be announced separately.
●The company does not violate Article 9.8.1 First of the "Shanghai Stock Exchange Stock Listing Rules"
Other risk warnings may be imposed as specified in Item (8) of this paragraph.
- Profit distribution plan for 2025
(1) Specific contents of the profit distribution plan
Audited by Daxin Accounting Firm (Special General Partnership) as of December 2025
On the 31st, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. (hereinafter referred to as "the Company" or "the Company")
The undistributed profit at the end of the parent company's statement was RMB 7,263,234,411.77.
According to the resolution of the 33rd meeting of the ninth session of the board of directors of the company, the company plans to implement in 2025
The total share capital on the equity registration date for equity distribution shall be the base for profit distribution. This profit distribution plan is as follows:
Next:
- The company plans to distribute a cash dividend of RMB 0.45 per share (tax included) to all shareholders.
As of December 31, 2025, the company's total share capital was 1,625,790,949 shares. Based on this calculation, the total share capital
It is planned to distribute cash dividends of RMB 731,605,927.05 (tax included). This year the company’s current
Total golden dividends (including interim cash dividends of RMB 650,316,379.60 distributed)
1,381,922,306.65 yuan, accounting for 46.32% of the net profit attributable to shareholders for the year.
There will be no conversion of capital reserve funds into share capital this year.
- If between the date of disclosure of this announcement and the equity registration date for equity distribution, the company
If the total share capital changes, the company plans to maintain the total distribution amount unchanged and adjust the distribution ratio per share accordingly.
Example. If the total share capital changes subsequently, specific adjustments will be announced separately.
(2) Explanation of whether other risk warning situations are involved
Item Current year Previous year Previous year
Total cash dividends (RMB) 1,381,922,306.65 1,300,632,759.20 1,217,717,420.80 Total amount of repurchase and cancellation (yuan) 0 0 0
Net profit attributable to shareholders of listed companies 2,983,113,594.80 2,835,496,163.51 4,055,678,691.49 Run (RMB) The parent company's statement at the end of the current year is not distributed. 7,263,234,411.77 Profit (RMB) Accumulated cash in the last three fiscal years 3,900,272,486.65 Total dividends (RMB) Cumulative repurchases in the past three fiscal years
Total amount written off (RMB) Average net profit for the past three fiscal years 3,291,429,483.27 Run (RMB) Accumulated cash in the last three fiscal years Total amount of dividends and repurchase cancellation (person 3,900,272,486.65 (RMB Yuan) Accumulated cash in the last three fiscal years Is the total amount of dividends and repurchases written off? No Less than 50 million yuan Cash dividend ratio (%) 118.50%
Is the cash dividend ratio less than 30%? No Whether it touches the Stock Listing Rules
Article 9.8.1 Paragraph 1 (8) No The provisions of this paragraph may be implemented by other
Risk warning situations
As shown in the table above, the company’s cumulative cash dividends and repurchases and write-offs in the past three fiscal years have totaled
The amount is higher than 30% of the average annual net profit in the last three fiscal years, and does not touch the Shanghai Stock Exchange
The provisions of Item (8) of Article 9.8.1, Paragraph 1 (8) of the Stock Listing Rules may be implemented in other ways.
Risk warning situations.
- Mid-term cash dividend plan for 2026
In order to improve investor returns and share operating results, according to Article 3 of the "Guidelines for the Supervision of Listed Companies"
No. - Cash Dividends of Listed Companies (Revised in 2025)" and other relevant regulations and combined with the company's actual
In this situation, the company plans to meet the conditions for cash dividends and does not affect the company's normal operations and sustainable development.
Under the circumstances, formulate a mid-term profit distribution plan for 2026 and implement equity distribution within the specified period,
The amount of mid-term cash dividends in 2026 shall not exceed the net profit attributable to shareholders of listed companies during the corresponding period.
Run. In order to simplify the dividend distribution procedure, the shareholders’ meeting is proposed to authorize the company’s board of directors to
Under the conditions, a mid-term dividend plan for 2026 will be formulated and implemented.
- Decision-making procedures implemented by the company
The company held the 33rd meeting of the ninth board of directors on March 20, 2026 to review
The meeting approved the "Company's 2025 Profit Distribution Plan and 2026 Interim Cash Dividend Regulations"
"Planning Proposal", the distribution plan is in line with the profit distribution policy stipulated in the "Articles of Association" and the company's
disclosed the shareholder return plan, agreed to submit the proposal to the company’s shareholders’ meeting for review, and agreed to submit
The shareholders' meeting is requested to authorize the board of directors to formulate and implement interim profit distribution matters.
"The Company's 2025 Profit Distribution Plan and 2026 Interim Cash Dividend Plan"
The "Proposal" still needs to be submitted to the company's 2025 annual shareholders' meeting for review.
- Related risk warnings
This profit distribution plan comprehensively takes into account the company’s development stage, future capital needs and other factors.
factors, will not have a significant impact on the company's operating cash flow, and will not affect the company's normal operations and
Long-term development; this profit distribution plan still needs to be submitted to the company’s 2025 annual shareholders’ meeting for review
It can only be implemented after approval. Investors are advised to pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.
March 20, 2026